))
Chikungunya Vaccine Trial: Exploring the Results
Manage episode 436702581 series 3517021
Sisällön tarjoaa ReachMD. ReachMD tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Host: Matt Birnholz, MD
Chikungunya is a mosquito-transmitted viral disease that is highly likely to spread globally through patients who are traveling. So a phase three clinical trial aimed to test the safety and immunogenicity of the VLA1553 vaccine against this virus. Dive in to learn about the methods and results of this trial with Dr. Matt Birnholz, ReachMD host. Valneva did not contribute to the educational content.
…
continue reading
Chikungunya is a mosquito-transmitted viral disease that is highly likely to spread globally through patients who are traveling. So a phase three clinical trial aimed to test the safety and immunogenicity of the VLA1553 vaccine against this virus. Dive in to learn about the methods and results of this trial with Dr. Matt Birnholz, ReachMD host. Valneva did not contribute to the educational content.
37 jaksoa
Jaa
